Neoplasm malignant
RecruitingZongertinib for Cancer in Patients Eligible for Early Access Treatment
- Disease:Neoplasm malignant
- Substances:Zongertinib
Finland- Participants:18–64 years · 65+ years
- Substances:Zongertinib
- Sponsor:HUS-yhtymae
Rare diseases
Investigational molecules
Locations
Back to Finland273 clinical trials in Tampere, Finland across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.
Our site in FinlandKliinisetTutkimukset.fi(opens in a new tab)
Finland
Finland
Finland
Finland
Finland
Finland
Finland
Finland
Finland
Finland
Finland
FinlandThe busiest research cities in the country
What the registry says about research in the country
Extensive research focusing on vaccine development against multiple viral infections, including influenza, RSV, and meningococcal disease. Clinical trials are evaluating novel immunization strategies for different age groups.
Multiple studies are investigating immune responses and long-term protection against respiratory infections.
Innovative trials exploring new treatments for various cancers, with emphasis on advanced solid tumors and blood cancers. Studies combine novel therapeutic approaches with existing treatments.
Focus on developing targeted therapies and improving treatment outcomes for cancer patients.
Research evaluating advanced diagnostic techniques, particularly in emergency medicine and acute conditions. Studies compare different imaging methods and their effectiveness.
Emphasis on improving diagnostic accuracy while considering patient safety.
Tell us about your condition – we search every trial in Europe and connect you with the right site.